IMS 2022 | Identification of myeloma high-risk subclones with single-cell technologies
Jill Corre
• 30 Aug 2022
Jill Corre, PharmD, PhD, The Cancer University Institute of Toulouse Oncopole (IUCT), Toulouse, France, comments on the use of single-cell technologies to identify patients with high-risk subclones at diagnosis to better stratify patients into standard and high-risk categories and thus help prevent early relapse. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
